Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2583787 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL30792927 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL30896020 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL30016334 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL18154894 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL30896027 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL31742570 | 0.93 | EPHX2 (0.44) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL28365887 | 0.85 | EPHX2 (0.46) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL6532381 | 0.83 | CASP3 (0.43) | EPHX2KMT2ACASP3 | |
| SCHEMBL8120555 | 0.83 | EPHX2 (0.44) | EPHX2FABP5FABP7KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660303-A2 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-3810626-B1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-12209145-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2025-01-28 | — | — | US | disclosed |
| US-12012468-B2 | Cyclic polypeptides for PCSK9 inhibition | MERCK SHARP & DOHME LLC (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | RA PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| US-7122521-B2 | COMPRISING TRIPEPTIDE UNIT OF THE FORMULA (flp-Yaa-Gly)N, WHERE Yaa IS ANY AMINO ACID, FLP IS 4(R)-FLUORO-L-PROLINE, AND N IS AT LEAST 3; INCREASED STABILITY; STRONGER TRIPLE HELIX THAN NATIVE COLLAGEN; FOR USE SUCH AS IN ARTIFICIAL SKIN | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2005000872-A2 | COLLAGEN MIMICS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20050004032-A1 | Collagen mimics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | EPHX2 3665/4885FABP5 786/4885FABP7 1281/4885 |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | EPHX2 4394/4885FABP5 1423/4885FABP7 726/4885 |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | PCSK9, LDLR, PCSK7 | EPHX2 3480/4885FABP5 689/4885FABP7 992/4885 |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | EPHX2 3517/4885FABP5 4703/4885FABP7 4408/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | EPHX2 4375/4885FABP5 1444/4885FABP7 722/4885 |
| US-12012468-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | EPHX2 3480/4885FABP5 689/4885FABP7 992/4885 |
| US-12209145-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | EPHX2 2049/4885FABP5 1809/4885FABP7 2407/4885 |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | EPHX2 2049/4885FABP5 1809/4885FABP7 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.